The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2025Path to Prevention (P2P) Platform Trial: A Phase 2A, Randomized, Double Blind, Placebo Controlled Study to Evaluate Investigational Interventions in Early-Stage Neuronal Alpha-Synuclein Disease (NSD)
Study Rationale: Assess the impact of putative NSD therapies in participants with Early Stage NSD on Dopamine Transporter Single-photon emission computed Tomography (DAT SPECT) imaging, clinical...
-
Research Grant, 2024SUPPLEMENT: MJFF Consortium on PRKN and PINK1
Study Rationale: Recessively inherited forms of Parkinson’s disease (PD) caused by mutations on both copies of the genes PRKN and PINK1 are unique in many aspects. Age at onset is mainly before the...
-
Research Grant, 2024Virtual Screening and Biochemical Confirmation of Small Molecule Activators of ATP10B
Study Rationale: Disruption of lysosomal glucosylceramide (GluCer) homeostasis is a key risk factor in Parkinson’s disease. ATP10B, a lysosomal GluCer exporter, has been linked to Parkinson’s through...
-
Therapeutic Pipeline Program, 2024Integrin CLOAKs as Novel Oral Therapeutics for Parkinson’s Disease
Study Rationale: Increased neuroinflammation promotes neuron injury and loss (neurodegeneration) and drives progression of Parkinson’s Disease (PD), suggesting that controlling neuroinflammation is an...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biomarkers, 2025EV-PREDICT: Identifying Early Biomarkers for Parkinson’s Disease in Blood-derived Neuronal Vesicles
Study Rationale: Parkinson’s disease (PD) is a common and growing brain disorder that currently has no cure and is difficult to diagnose early. A key feature of PD is the abnormal buildup of a protein...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025SUPPLEMENT: IRL757 for the Treatment of Apathy in Parkinson's Disease
Study Rationale: People with PD frequently develop a loss of motivation and initiative. This phenomenon is called apathy and can be a very burdensome symptom of PD, affecting not only the patient but...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.